Perivascular macrophages in high-fat diet-induced hypothalamic inflammation
Related Experiment Video
Updated: Sep 20, 2025

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation
Published on: April 3, 2017
Natalia F Mendes1, Licio A Velloso2,3
1Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas, Rua Carl Von Linnaeus s/n, Instituto de Biologia - Bloco Z. Campus Universitário Zeferino Vaz - Barão Geraldo, Campinas, SP, 13083-864, Brazil. natalia.mendesss@gmail.com.
Abstract:
Brain macrophages and microglia are centrally involved in immune surveillance of the central nervous system. Upon inflammatory stimuli, they become reactive and release key molecules to prevent further damage to the neuronal network. In the hypothalamic area, perivascular macrophages (PVMs) are the first line of host defence against pathogenic organisms, particles and/or substances from the blood. They are distributed throughout the circumventricular organ median eminence, wrapping endothelial cells from fenestrated portal capillaries and in the hypothalamic vascular network, where they are localised in the perivascular space of the blood-brain barrier (BBB). Some studies have indicated that PVMs from the hypothalamus increase the expression of inducible nitric oxide synthase and vascular endothelial growth factor upon feeding for a long time on a high-fat diet. This adaptive response contributes to the impairment of glucose uptake, facilitates BBB leakage and leads to increased lipid and inflammatory cell influx towards the hypothalamic parenchyma. Despite these early findings, there is still a lack of studies exploring the mechanisms by which PVMs contribute to the development of obesity-related hypothalamic dysfunction, particularly at the early stages when there is chemotaxis of peripheral myeloid cells into the mediobasal hypothalamus. Here, we reviewed the studies involving the ontogeny, hallmarks and main features of brain PVMs in vascular homeostasis, inflammation and neuroendocrine control. This review provides a framework for understanding the potential involvement of PVMs in diet-induced hypothalamic inflammation.
Insights
Perivascular macrophages (PVMs) in the hypothalamus are key in brain defense. This review explores their role in diet-induced inflammation and obesity, highlighting early-stage mechanisms.
Area of Science:
- Neuroimmunology
- Vascular Biology
- Metabolic Neuroscience
Background:
- Brain macrophages and microglia are crucial for central nervous system immune surveillance.
- Perivascular macrophages (PVMs) in the hypothalamus act as the initial defense against blood-borne substances.
- PVMs are strategically located in the median eminence and hypothalamic vasculature, interacting with the blood-brain barrier (BBB).
Purpose of the Study:
- To review the ontogeny, characteristics, and functions of brain PVMs.
- To explore the mechanisms linking PVMs to diet-induced hypothalamic inflammation and obesity.
- To provide a framework for understanding PVM involvement in early-stage obesity-related hypothalamic dysfunction.
Main Methods:
- Literature review of studies on PVMs in vascular homeostasis, inflammation, and neuroendocrine control.
- Analysis of PVM responses to inflammatory stimuli and high-fat diets.
- Examination of PVMs' role in chemotaxis of myeloid cells into the hypothalamus.
Main Results:
- Hypothalamic PVMs upregulate nitric oxide synthase and vascular endothelial growth factor in response to prolonged high-fat diet.
- These adaptive responses impair glucose uptake, increase BBB permeability, and promote inflammatory cell infiltration.
- Evidence suggests PVMs contribute to hypothalamic dysfunction during early stages of diet-induced obesity.
Conclusions:
- PVMs play a significant role in hypothalamic inflammation associated with diet-induced obesity.
- Understanding PVM mechanisms is crucial for addressing obesity-related neuroendocrine and metabolic disorders.
- Further research into PVMs offers potential therapeutic targets for metabolic diseases.

